Skip to main content

Advertisement

Figure 4 | Molecular Cancer

Figure 4

From: Inhibition of HSP27 alone or in combination with pAKT inhibition as therapeutic approaches to target SPARC-induced glioma cell survival

Figure 4

Inhibition of pAKT eliminates SPARC-induced survival in temozolomide (TMZ). A. Representative Western blots of C1.1 control GFP- or H2 SPARC-GFP-expressing cells in the absence 0 (0.1% DMSO control) or presence of 100 μM TMZ ± AKT inhibitor IV at indicated concentrations for 48 hr before lysing. Arrows indicate ≥ 2-fold increases or decreases due to ± TMZ treatment and asterisks indicate ≥ 2-fold increases or decreases due to AKT inhibitor IV treatment. B. Means for surviving fraction ± SD of C1.1 or H2 cells treated ± AKT IV inhibitor ± TMZ plating 1500 cells/60-mm dish are presented. For C1.1 * p = 0.0022, **, *** p = 0.0001. For H2 *,**,*** p = 0.0001. C. Means for surviving fraction ± SD of C1.1 or H2 cells treated ± AKT IV inhibitor ± TMZ plating 1500 cells/60-mm dish are presented. * p = 0.014, ** p = 0.0006, *** p ≤ 0.0001, **** p ≤ 0.0003, ***** p ≤ 0.03 except H2 0.25 AKT inhibitor IV (40 vs. 80 ≤ μM TMZ) is not significant, ****** p ≤ 0.008. NS - not significant. Plating 3000 cells gave similar results.

Back to article page